Skip to main content

Table 1 Demographic characteristics of study participants

From: Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study

Characteristics Total n=82
Age 41 (36–48)
Race  
   White 28 (34%)
   Black 46 (56%)
   Other 8 (10%)
Risk Factor  
   Injection drug use 11 (13%)
   Endemic country 27 (33%)
   Heterosexual contact 59 (72%)
   Blood transfusion 7 (9%)
   Unknown 8 (10%)
Years since HIV diagnosis 7 (3–11)
CD4+ cell count prior to cART (μL) 232 (128–400)
Current CD4+ cell count (μL) 487 (380–621)
VL prior to cART (log10 copies/mL) 4.5 (3.0-5.0)
AIDS diagnosis 19 (23%)
Months since start of cART 20 (9–45)
cART includes PI 47 (57%)
cART includes NNRTI 35 (43%)
Missed ARV dose in past week 6 (7%)
Hepatitis B co-infection 2 (2%)
Hepatitis C co-infection 10 (12%)
Weight (kg) 67.3 (60.3-81.5)
BMI 25.8 (22.4-31.3)
Menstrual status  
   Regular periods 44 (54%)
   Irregular periods 10 (12%)
   Current amenorrhea 9 (11%)
   Menopausal 19 (23%)
  1. Continuous variables presented as medians with interquartile range; categorical variables presented as n (%).VL, viral load; AIDS, acquired immunodeficiency syndrome; cART, combination antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; ARV, antiretroviral; BMI, body mass index.